A note from our editorial director of events on the 2025 STAT Summit. Early access pricing extended through Friday, August 15 — join us live in Boston this October.
STAT turns 10 in November. That led us to think about all that has happened in biomedicine over the past decade, from a revolution in gene editing to a pandemic to the Aduhelm fiasco — and to wonder what's next.
Our annual STAT Summit, being held on Oct. 15 and 16 in Boston will focus on the next 10 years. Given what we've seen in the past, what can we expect in the future? And I promise we will touch on the above topics, too.
Already, a stunning lineup is taking shape. Daniel Skovronsky, probably the most successful pharma R&D chief right now, will talk about where drug research is headed. Joe Kennedy, the former congressman, will walk us through the politics and policy around health, from Medicare and Medicaid to mental health and marijuana legalization.
Alondra Nelson, one of the deepest thinkers about the relationship between human beings and the technology they use, will sit down for an in-depth discussion of how to stay human in the age of medical AI. A top cancer researcher, Miriam Merad, will explain the potential future of cancer immunotherapy.
We'll have Ben Wolf, the veteran drug hunter who is now chief medical officer of Google spinout Isomorphic Labs; Emma Walmsley, the CEO of GSK; and Michelle Xia, the CEO of Akeso, one of the hottest biotech companies to emerge from China.
The president of the American Academy of Addiction Medicine will explain what his experience running drug testing for the National Basketball Association says about the future of treating and preventing substance abuse in the U.S. And a MacArthur "genius" will demo amazing technology that allows researchers to track patients' movements in space and time.
That's just the start. We have a lot more coming. But this is your last chance to buy a ticket at early access prices. I really think that you should — and that the investment will pay off in dividends of knowledge and understanding.
No comments